Thyme Care Secures $97M to Drive Value-Based Cancer Care
Becker's Hospital Review
|
Contributed by: Kate Gamble
Summary
Thyme Care, a Nashville-based healthcare company, has secured $97 million in Series D funding, bringing its total capital to $275 million. This financing, supported by both existing and new investors like CVS Health Ventures and Humana, aims to enhance its value-based cancer care model, which serves 8 million Americans and manages over $5 billion in oncology spending. Thyme Care's approach, which includes electronic patient-reported outcome surveys, has resulted in significantly reduced emergency room visits and hospital admissions, while improving operational efficiency for partner practices. These advancements underscore the potential of technology-driven solutions to streamline care and improve patient outcomes in oncology.
